The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

deltagen.com

Total Raised

$37.05M

Investors Count

14

Deal Terms

1

Benten BioServices Funding, Benten BioServices Valuation & Benten BioServices Revenue

6 Fundings

Benten BioServices's latest funding round was a PIPE - II for $10M on April 18, 2003.

Benten BioServices's valuation in August 2000 was $432.07M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

4/18/2003

PIPE - II

$10M

0

FY undefined

5/8/2002

PIPE

$99M

0

FY undefined

0

8/3/2000

IPO

$99M

$432.07M

0

FY undefined

10

1/24/2000

Series B

$99M

0

FY undefined

0

7/1/1998

Series A

$99M

0

FY undefined

0

Date

4/18/2003

5/8/2002

8/3/2000

1/24/2000

7/1/1998

Round

PIPE - II

PIPE

IPO

Series B

Series A

Amount

$10M

$99M

$99M

$99M

$99M

Investors

Valuation

$432.07M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

10

0

0

Financials

Income Statement

Income Statement

12/31/2021

12/31/2020

12/31/2019

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2021

12/31/2020

12/31/2019

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2021

12/31/2020

12/31/2019

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Benten BioServices Deal Terms

1 Deal Term

Benten BioServices's deal structure is available for 1 funding round, including their IPO from August 03, 2000.

Round

IPO

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Benten BioServices Investors

14 Investors

Benten BioServices has 14 investors. aPriori Capital Partners invested in Benten BioServices's PIPE - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/24/2000

4/18/2003

3
Series B, PIPE (2002), PIPE - II (2003)

Private Equity

New York

1/24/2000

4/18/2003

3
Series B, PIPE (2002), PIPE - II (2003)

Venture Capital

New York

1/24/2000

4/18/2003

2
Series B, PIPE - II (2003)

Private Equity

Massachusetts

00/00/0000

00/00/0000

Baccharis Capital

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Castle Creek Capital

Subscribe to see more

Private Equity

California

First funding

1/24/2000

1/24/2000

1/24/2000

00/00/0000

00/00/0000

Last Funding

4/18/2003

4/18/2003

4/18/2003

00/00/0000

00/00/0000

Investor

Baccharis Capital

Castle Creek Capital

Rounds

3
Series B, PIPE (2002), PIPE - II (2003)
3
Series B, PIPE (2002), PIPE - II (2003)
2
Series B, PIPE - II (2003)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Private Equity

Venture Capital

Private Equity

Venture Capital

Private Equity

Location

New York

New York

Massachusetts

California

California

Benten BioServices Acquisitions

2 Acquisitions

Benten BioServices acquired 2 companies. Their latest acquisition was Benten BioServices (acquired by Deltagen) on December 10, 2009.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/10/2009

Debt

$99M

$4.33M

Acquired

1

7/17/2001

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

12/10/2009

7/17/2001

Investment Stage

Debt

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$4.33M

$99M

Note

Acquired

Subscribe to see more

Sources

1

0

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Q
QPS

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

Presage Biosciences Logo
Presage Biosciences

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

A
Allozyne

Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.

Shamrock Structures Logo
Shamrock Structures

Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.